Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiff Oncology (CRDF) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Cardiff Oncology (CRDF) over the last 16 years, with Q3 2025 value amounting to $66.9 million.

  • Cardiff Oncology's Shares Outstanding (Diluted Average) rose 4270.56% to $66.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.9 million, marking a year-over-year increase of 4270.56%. This contributed to the annual value of $47.6 million for FY2024, which is 665.44% up from last year.
  • Cardiff Oncology's Shares Outstanding (Diluted Average) amounted to $66.9 million in Q3 2025, which was up 4270.56% from $66.5 million recorded in Q2 2025.
  • Cardiff Oncology's 5-year Shares Outstanding (Diluted Average) high stood at $66.9 million for Q3 2025, and its period low was $37.2 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $46.9 million, with a median of $44.7 million in 2023.
  • As far as peak fluctuations go, Cardiff Oncology's Shares Outstanding (Diluted Average) surged by 16746.48% in 2021, and later increased by 0.22% in 2024.
  • Quarter analysis of 5 years shows Cardiff Oncology's Shares Outstanding (Diluted Average) stood at $39.0 million in 2021, then increased by 11.71% to $43.6 million in 2022, then grew by 2.47% to $44.7 million in 2023, then increased by 6.65% to $47.6 million in 2024, then surged by 40.35% to $66.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $66.9 million for Q3 2025, versus $66.5 million for Q2 2025 and $66.5 million for Q1 2025.